LogicBio Therapeutics LOGC Stock
LogicBio Therapeutics Price Chart
LogicBio Therapeutics LOGC Financial and Trading Overview
LogicBio Therapeutics stock price | 2.07 USD |
Previous Close | 2.07 USD |
Open | 2.06 USD |
Bid | 0 USD x 46000 |
Ask | 0 USD x 900 |
Day's Range | 2.06 - 2.07 USD |
52 Week Range | 0.26 - 3.4 USD |
Volume | 152.92K USD |
Avg. Volume | 566.21K USD |
Market Cap | 68.23M USD |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.5 USD |
LOGC Valuation Measures
Enterprise Value | 47.43M USD |
Trailing P/E | N/A |
Forward P/E | -3.3934424 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.341926 |
Price/Book (mrq) | 4.3396225 |
Enterprise Value/Revenue | 4.408 |
Enterprise Value/EBITDA | -1.882 |
Trading Information
LogicBio Therapeutics Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -26.85% |
S&P500 52-Week Change | -11.95% |
52 Week High | 3.4 USD |
52 Week Low | 0.26 USD |
50-Day Moving Average | 1.47 USD |
200-Day Moving Average | 0.76 USD |
LOGC Share Statistics
Avg. Volume (3 month) | 566.21K USD |
Avg. Daily Volume (10-Days) | 148.33K USD |
Shares Outstanding | 32.96M |
Float | 16.51M |
Short Ratio | 0.23 |
% Held by Insiders | 8.93% |
% Held by Institutions | 48.70% |
Shares Short | 274.42K |
Short % of Float | 1.16% |
Short % of Shares Outstanding | 0.82% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | September 30, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -246.71% |
Operating Margin (ttm) | -240.63% |
Gross Margin | -185.14% |
EBITDA Margin | -234.28% |
Management Effectiveness
Return on Assets (ttm) | -30.30% |
Return on Equity (ttm) | -97.40% |
Income Statement
Revenue (ttm) | 10.76M USD |
Revenue Per Share (ttm) | 0.33 USD |
Quarterly Revenue Growth (yoy) | 28.19% |
Gross Profit (ttm) | -22759000 USD |
EBITDA | -25207000 USD |
Net Income Avi to Common (ttm) | -26544000 USD |
Diluted EPS (ttm) | -1.116 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 30.78M USD |
Total Cash Per Share (mrq) | 0.93 USD |
Total Debt (mrq) | 9.98M USD |
Total Debt/Equity (mrq) | 63.4 USD |
Current Ratio (mrq) | 1.995 |
Book Value Per Share (mrq) | 0.477 |
Cash Flow Statement
Operating Cash Flow (ttm) | -25261000 USD |
Levered Free Cash Flow (ttm) | -12375375 USD |
Profile of LogicBio Therapeutics
Country | United States |
State | MA |
City | Lexington |
Address | 65 Hayden Avenue |
ZIP | 02421 |
Phone | 617 245 0399 |
Website | https://www.logicbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 62 |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Q&A For LogicBio Therapeutics Stock
What is a current LOGC stock price?
LogicBio Therapeutics LOGC stock price today per share is 2.07 USD.
How to purchase LogicBio Therapeutics stock?
You can buy LOGC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for LogicBio Therapeutics?
The stock symbol or ticker of LogicBio Therapeutics is LOGC.
Which industry does the LogicBio Therapeutics company belong to?
The LogicBio Therapeutics industry is Biotechnology.
How many shares does LogicBio Therapeutics have in circulation?
The max supply of LogicBio Therapeutics shares is 32.96M.
What is LogicBio Therapeutics Price to Earnings Ratio (PE Ratio)?
LogicBio Therapeutics PE Ratio is 0.00000000 now.
What was LogicBio Therapeutics earnings per share over the trailing 12 months (TTM)?
LogicBio Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the LogicBio Therapeutics company belong to?
The LogicBio Therapeutics sector is Healthcare.
LogicBio Therapeutics LOGC included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}